Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dimitrios Tzachanis has a total of 102 co-authors. Here are the top co-authors by number of shared publications:

  • Ah-Reum Jeong

    Department of Medicine, Division of Blood and Marrow Transplantation, University of California San Diego, La Jolla, CA 92093, USA

    3 shared publications
  • Aaron M. Goodman

    Department of Medicine, Division of Blood and Marrow Transplantation, University of California San Diego, La Jolla, CA 92093, USA

    2 shared publications
  • Aaron Trando

    School of Medicine, University of California San Diego, La Jolla, CA 92093, USA

    2 shared publications
  • Carolyn Mulroney

    Division of Blood and Marrow Transplantation, Department of Medicine, University of California San Diego, La Jolla, CA

    2 shared publications
  • Edward D. Ball

    Division of Blood and Marrow Transplantation, Department of Medicine, University of California San Diego, La Jolla, CA

    2 shared publications
  • Katarina Luptakova

    Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA

    2 shared publications

Latest Publications

  • Open Access

    Ruxolitinib for graft-versus-host disease prophylaxis following tacrolimus toxicity: A case series

    by Nidhi Kanchan, Janine Martino, Dimitrios Tzachanis, Ila M Saunders

    Introduction: The data on the safety and feasibility of transitioning from tacrolimus to ruxolitinib for graft-versus-host disease (GVHD) prophylaxis in the early post-allogeneic hematopoietic stem cell transplantation (allo-HCT) period is lacking. Optimal dosing and timing of ruxolitinib remains unclear. Case Report: We describe four allo-HCT recipients who required early tacrolimus discontinuation due to neurotoxicity (n = 2) or nephrotoxicity (n = 2) and were transitioned to ruxolitinib for GVHD prophylaxis. The patients ranged from 23 to 74 years of age and received reduced-intensity conditioning with standard post-transplant cyclophosphamide-based prophylaxis. Tacrolimus was discontinued between Days +27 and +44. Management and Outcomes: Ruxolitinib was initiated between Days +29 and +53 at doses ranging between 5 to 15 milligrams per day with the use of a short prednisone bridge in one patient. All four patients experienced resolution of their tacrolimus-related toxicity, and no acute or chronic GVHD events were observed at last follow-up. The primary ruxolitinib-associated adverse event was cytopenia, which was expected. Full or near full chimerism was maintained in all patients. Discussion: This case series provides early evidence for a safe switch from tacrolimus to ruxolitinib for GVHD prophylaxis in the post-allo-HCT setting with effective GVHD control. Ruxolitinib 5 to 15 milligrams per day appear reasonable when tacrolimus discontinuation is necessary. Prospective studies are needed to define optimal dosing and transition strategies.

  • Open Access

    Factors Associated with Increased Healthcare Utilization Within 30 and 90 Days Post-Discharge of CAR-T Cell Therapy in Patients with R/R LBCL

    by Philip Yeung, Aaron Trando, Ah-Reum Jeong, Dimitrios Tzachanis

    Background/Objectives: CAR T-cell therapy is a highly efficacious therapy option for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), but its widespread use is currently limited by safety concerns and high healthcare costs. Methods: We evaluated 66 patients with R/R LBCL treated with tisagenlecleucel or axicabtagene ciloleucel between 2016 and 2022 at a single institution to identify factors associated with increased healthcare utilization. Results: The median age of our cohort was 59.5 years, with 22.7% over the age of 70. The median length of stay (LOS) during the initial hospitalization was 12 days (range, 7–62 days). Longer initial hospital LOS was linked to higher age-adjusted HCT-CI score (IRR 1.08; 95% CI, 1.01 to 1.15; p = 0.0203), thrombocytopenia grade 3–4 (IRR 1.32; 95% CI, 1.07 to 1.63; p = 0.0091), and first ICU admission (IRR 1.81; 95% CI, 1.37 to 2.38; p < 0.00001). Thirty- and 90-day readmission rates post-discharge after receiving CAR T-cell therapy were 21.2% and 28.8%, respectively. Multiple readmissions within 90 days after initial hospital discharge were observed in 15% of patients. Longer 30-day readmission LOS was linked to initial hospital LOS (IRR 1.23; 95% CI, 1.11 to 1.35; p < 0.0001) but outpatient follow-up was associated with shorter 30-day readmission LOS (IRR 0.43; 95% CI, 0.26–0.69; p = 0.0005). Factors associated with longer 90-day readmission LOS included a greater number of ER visits within 60 days of CAR T-cell therapy (IRR 3.10; 95% CI, 2.15–4.46), prior 30-day readmission LOS (IRR 1.35; 95% CI, 1.14–1.60), and SUVmax at Day 30 (IRR 1.06; 95% CI, 1.03–1.09) (all p-values < 0.0001). Conclusions: Our findings identify key clinical and utilization variables associated with initial and repeat hospitalizations post-CAR T-cell therapy, emphasizing the need for targeted interventions to reduce readmissions and optimize post-discharge care.

  • Open Access

    A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abatacept

    by Divya Koura, Kaitlyn Dykes, Aaron Goodman, Caitlin Costello, Carolyn Mulroney, James K. Mangan, Tiffany N. Tanaka, Edward D. Ball, Ayad Hamdan, Ah-Reum Jeong, et al.

    We conducted a prospective randomized clinical trial to investigate the combination of posttransplant cyclophosphamide (PTCy) and abatacept (Aba) for graft-versus-host disease (GVHD) prophylaxis. Patients with hematologic malignancies undergoing an allogeneic transplant from an 8/8 matched related or unrelated donor were randomized 1:1 to tacrolimus and methotrexate (standard-of-care arm [SOC]) or PTCy on days +3 and +4, followed by Aba on an extended schedule: days +5, +14, and +28, and every 4 weeks up to day +168 (PTCy+Aba). All patients received peripherally collected stem cells. The primary end point was moderate and severe chronic GVHD at 1 year. Following US Food and Drug Administration approval of Aba for GVHD prophylaxis leading to change in institutional SOC, the trial was amended to enroll only on the PTCy+Aba arm. A total of 25 patients enrolled on PTCy+Aba, and 15 on SOC. The trial met its primary end point: Kaplan-Meier estimates of moderate and severe chronic GVHD were 0% on the PTCy+Aba and 65.8% on the SOC arm (P < .0001). GVHD-free, relapse-free survival (GRFS) was 62.5% on PTCy+Aba and 24.1% on SOC (P = .010). There were no treatment-related deaths on PTCy+Aba and 2 on SOC. Overall survival (PTCy+Aba, 92%; SOC, 80%; P = .28), disease-free survival (PCTy+Aba, 68%; SOC, 92.9%; P = .105), and infection rates at 1 year were similar. Grade 3/4 acute GVHD rate was 4.2% on PTCy+Aba and 21.4% on SOC (P = .092). PTCy+Aba preserved regulatory T-cell proliferation and increased CD16+CD56dim cytotoxic natural killer cells. In conclusion, PTCy+Aba is well tolerated and associated with reduced chronic GVHD and improved GRFS. This trial was registered at www.ClinicalTrials.gov as #NCT03680092.


  • A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503)

    by Brian A. Jonas, Samantha C. Fisch, Peter T. Curtin, Gary J. Schiller, Deepa Jeyakumar, Dimitrios Tzachanis, Rafael Bejar, Lihong Qi, Matthew J. Wieduwilt, Joseph M. Tuscano, et al.


  • Open Access

    Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution Experience

    by Aaron Trando, Anna Ter-Zakarian, Phillip Yeung, Aaron M. Goodman, Ayad Hamdan, Michael Hurley, Ah-Reum Jeong, Dimitrios Tzachanis

    Chimeric antigen receptor T-cell (CAR T-cell) therapy has revolutionized the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We describe the real-world baseline characteristics, efficacy, safety, and post-relapse outcomes of adult patients with R/R LBCL who received CAR T-cell therapy at the University of California San Diego. A total of 66 patients with LBCL were treated with tisagenlecleucel or axicabtagene ciloleucel. The median age was 59.5, and 21% were over 70 years old. Additionally, 20% of the patients had an Eastern Cooperative Oncology Group (ECOG) performance score of ≥2. Cytokine release syndrome incidence was 88%; immune effector cell-associated neurotoxicity syndrome incidence was 56%. All-grade infection occurred in 48% of patients and in 79% of patients > 70 years old. Complete response (CR) was achieved in 53% and partial response in 14%. Median progression-free survival (PFS) was 10.3 months; median overall survival (OS) was 28.4 months. Patients who relapsed post-CAR T-cell therapy had poor outcomes, with a median OS2 of 4.8 months. Upon multivariate analysis, both ECOG (HR 2.65, 95% CI: 1.30–5.41; p = 0.007) and ≥2 sites of extranodal involvement (HR 2.22, 95% CI: 1.15–4.31; p = 0.018) were significant predictors of PFS. Twenty-six patients were R/R to CAR T-cell therapy; six patients were in remission at the time of data cut off, one of whom received allogeneic transplant. Overall, older patients can safely undergo CAR T-cell therapy, despite the increased risk of all-grade infection. In our cohort, ECOG performance score and ≥2 sites of extranodal disease are significant predictors of PFS.


  • Open Access

    Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

    by Mahmoud Elsawy, Julio C. Chavez, Irit Avivi, Jean-François Larouche, Luciano Wannesson, Kate Cwynarski, Keren Osman, Kelly Davison, Jakob D. Rudzki, Saurabh Dahiya, et al.

    Here, we report the first comparative analysis of patient-reported outcomes (PROs) with chimeric antigen receptor T-cell therapy vs standard-of-care (SOC) therapy in second-line relapsed/refractory large B-cell lymphoma (R/R LBCL) from the pivotal randomized phase 3 ZUMA-7 study of axicabtagene ciloleucel (axi-cel) vs SOC. PRO instruments were administered at baseline, day 50, day 100, day 150, month 9, and every 3 months from randomization until 24 months or an event-free survival event. The quality of life (QoL) analysis set comprised patients with a baseline and ≥1 follow-up PRO completion. Prespecified hypotheses for Quality of Life Questionnaire-Core 30 (QLQ-C30) physical functioning, global health status/QoL, and EQ-5D-5L visual analog scale (VAS) were tested using mixed-effects models with repeated measures. Clinically meaningful changes were defined as 10 points for QLQ-C30 and 7 for EQ-5D-5L VAS. Among 359 patients, 296 (165 axi-cel, 131 SOC) met inclusion criteria for QoL analysis. At day 100, statistically significant and clinically meaningful differences in mean change of scores from baseline were observed favoring axi-cel over SOC for QLQ-C30 global health status/QoL (estimated difference 18.1 [95% confidence interval (CI), 12.3-23.9]), physical functioning (13.1 [95% CI, 8.0-18.2]), and EQ-5D-5L VAS (13.7 [95% CI, 8.5-18.8]; P < .0001 for all). At day 150, scores significantly favored axi-cel vs SOC for global health status/QoL (9.8 [95% CI, 2.6-17.0]; P = .0124) and EQ-5D-5L VAS (11.3 [95% CI, 5.4-17.1]; P = .0004). Axi-cel showed clinically meaningful improvements in QoL over SOC. Superior clinical outcomes and favorable patient experience with axi-cel should help inform treatment choices in second-line R/R LBCL. This trial was registered at www.clinicaltrials.gov as #NCT03391466.


  • Open Access

    Recent Advances in CAR T-Cell Therapy for Patients with Chronic Lymphocytic Leukemia

    by Benjamin M. Heyman, Dimitrios Tzachanis, Thomas J. Kipps

    Chimeric antigen receptor T cells (CAR T cells) have resulted in dramatic treatment responses for patients with hematologic malignancies, resulting in improved survival for patients with intractable disease. The first patient treated with CD19 directed CAR T cell therapy had chronic lymphocytic leukemia (CLL) and achieved a complete remission. Subsequent clinical trials have focused largely on patients with other B-cell hematologic malignancies, owing to the fact that CAR T cell therapy for patients with CLL has met with challenges. More recent clinical trials have demonstrated CAR T cell therapy can be well tolerated and effective for patients with CLL, making it a potential treatment option for patients with this disease. In this article we review the background on CAR T cells for the treatment of patients with CLL, focusing on the unique obstacles that patients with CLL present for the development of adoptive T cell therapy, and the novel approaches currently under development to overcome these hurdles.


  • Open Access

    Assessing CAR T-Cell Therapy Response Using Genome-Wide Sequencing of Cell-Free DNA in Patients With B-Cell Lymphomas

    by Aaron M. Goodman, Kimberly A. Holden, Ah-Reum Jeong, Lisa Kim, Kerry D. Fitzgerald, Eyad Almasri, Graham McLennan, Marcia Eisenberg, Amin H. Jahromi, Carl Hoh, et al.